Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-first microcap is using its balance sheet to accumulate BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Spyre Therapeutics Inc SYRE

Healthcare Biotechnology
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD... see more

Recent & Breaking News (NDAQ:SYRE)

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

GlobeNewswire 1 hour ago

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

GlobeNewswire 1 day ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

GlobeNewswire 3 days ago

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

GlobeNewswire 3 days ago

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

GlobeNewswire 6 days ago

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire 13 days ago

Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026

GlobeNewswire March 16, 2026

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire March 6, 2026

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire February 24, 2026

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

GlobeNewswire February 19, 2026

Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach

GlobeNewswire February 18, 2026

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire February 6, 2026

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire January 23, 2026

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

GlobeNewswire January 12, 2026

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire January 8, 2026

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire December 5, 2025

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire November 7, 2025

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 4, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

GlobeNewswire November 4, 2025

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswire October 29, 2025

Podcasts